Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 157K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Haurum, J. S. Articles by Elliott, T. Search for Related Content PubMed PubMed Citation Articles by Haurum, J. S. Articles by Elliott, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB L-SERINE Social Bookmarking                            What's this?

Brief Definitive Report

^a From the Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, England
^b From the Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, England
^c Institute of Cancer Biology, Danish Cancer Society, 2100 Copenhagen, Denmark
^d Unit of Glycoconjugate Chemistry, CID-CSIC, E08034 Barcelona, Spain
^e Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands

Antigens presented by class I major histocompatibility complex (MHC) molecules for recognition by cytotoxic T lymphocytes consist of 8–10-amino-acid-long cytosolic peptides. It is not known whether posttranslationally modified peptides are also presented by class I MHC molecules in vivo. Many different posttranslational modifications occur on cytoplasmic proteins, including a cytosolic O-β-linked glycosylation of serine and threonine residues with N-acetylglucosamine (GlcNAc). Using synthetic glycopeptides carrying the monosaccharide O-β-GlcNAc substitution on serine residues, we have shown that glycopeptides bind efficiently to class I MHC molecules and elicit a glycopeptide-specific cytotoxic T lymphocyte response in mice. In this study, we provide evidence that peptides presented by human class I MHC molecules in vivo encompass a small, significant amount of glycopeptides, constituting up to 0.1% of total peptide. Furthermore, we find that carbohydrate structures present on glycopeptides isolated from class I MHC molecules are dominated by the cytosolic O-β-GlcNAc substitution, and synthetic peptides carrying this substitution are efficiently transported by TAP (transporter associated with antigen presentation) into the endoplasmic reticulum. Thus, in addition to unmodified peptides, posttranslationally modified cytosolic peptides carrying O-β-linked GlcNAc can be presented by class I MHC molecules to the immune system.

Key Words: glycopeptides/immunology • class I histocompatibility antigens • posttranslational protein processing • antigen presentation • acetylglucosamine

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Ninkovic, T., Hanisch, F.-G. (2007). O-Glycosylated Human MUC1 Repeats Are Processed In Vitro by Immunoproteasomes. J. Immunol. 179: 2380-2388 [Abstract] [Full Text]  
• Young, D. C., Moody, D. B. (2006). T-cell recognition of glycolipids presented by CD1 proteins. Glycobiology 16: 103R-112R [Abstract] [Full Text]  
• Monzavi-Karbassi, B., Luo, P., Jousheghany, F., Torres-Quinones, M., Cunto-Amesty, G., Artaud, C., Kieber-Emmons, T. (2004). A Mimic of Tumor Rejection Antigen-Associated Carbohydrates Mediates an Antitumor Cellular Response. Cancer Res. 64: 2162-2166 [Abstract] [Full Text]  
• Xu, Y., Gendler, S. J., Franco, A. (2004). Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas. JEM 199: 707-716 [Abstract] [Full Text]  
• Apostolopoulos, V., Yuriev, E., Ramsland, P. A., Halton, J., Osinski, C., Li, W., Plebanski, M., Paulsen, H., McKenzie, I. F. C. (2003). A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl. Acad. Sci. USA 100: 15029-15034 [Abstract] [Full Text]  
• Birnboim, H. C., Lemay, A.-M., Lam, D. K. Y., Goldstein, R., Webb, J. R. (2003). Cutting Edge: MHC Class II-Restricted Peptides Containing the Inflammation-Associated Marker 3-Nitrotyrosine Evade Central Tolerance and Elicit a Robust Cell-Mediated Immune Response. J. Immunol. 171: 528-532 [Abstract] [Full Text]  
• Werdelin, O., Meldal, M., Jensen, T. (2002). Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc. Natl. Acad. Sci. USA 99: 9611-9613 [Full Text]  
• Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., Dwek, R. A. (2001). Glycosylation and the Immune System. Science 291: 2370-2376 [Abstract] [Full Text]  
• Zarling, A. L., Ficarro, S. B., White, F. M., Shabanowitz, J., Hunt, D. F., Engelhard, V. H. (2000). Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo. JEM 192: 1755-1762 [Abstract] [Full Text]  
• Yague, J., Alvarez, I., Rognan, D., Ramos, M., Vazquez, J., de Castro, J. A. L. (2000). An N-Acetylated Natural Ligand of Human Histocompatibility Leukocyte Antigen (Hla)-B39: Classical Major Histocompatibility Complex Class I Proteins Bind Peptides with a Blocked Nh2 Terminus in Vivo. JEM 191: 2083-2092 [Abstract] [Full Text]  
• Hudrisier, D., Riond, J., Mazarguil, H., Gairin, J. E. (2001). Pleiotropic Effects of Post-translational Modifications on the Fate of Viral Glycopeptides as Cytotoxic T Cell Epitopes. J. Biol. Chem. 276: 38255-38260 [Abstract] [Full Text]  
• Comer, F. I., Hart, G. W. (2000). O-Glycosylation of Nuclear and Cytosolic Proteins. DYNAMIC INTERPLAY BETWEEN O-GlcNAc AND O-PHOSPHATE. J. Biol. Chem. 275: 29179-29182 [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS